NASDAQ: ENTXEntera Bio Ltd Stock
$0.79+0.02 (+2.6%)
Updated May 26, 2023
ENTX Price
$0.79
Fair Value Price
$1.21
Market Cap
$22.65M
52 Week Low
$0.47
52 Week High
$2.38
P/E
-1.97x
P/B
2.25x
P/S
506.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$66.00k
Earnings
-$11.48M
Gross Margin
28.8%
Operating Margin
-17,171.21%
Profit Margin
-17,389.4%
Debt to Equity
0.15
Operating Cash Flow
-$9M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENTX Overview
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENTX ($0.79) is undervalued by 35.21% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ENTX ($0.79) is significantly undervalued by 35.21% relative to our estimate of its Fair Value price of $1.21 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ENTX due diligence checks available for Premium users.
Be the first to know about important ENTX news, forecast changes, insider trades & much more!
ENTX News
Valuation
ENTX fair value
Fair Value of ENTX stock based on Discounted Cash Flow (DCF)
Price
$0.79
Fair Value
$1.21
Undervalued by
34.88%
ENTX ($0.79) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ENTX ($0.79) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ENTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ENTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.97x
Industry
11.86x
Market
54.23x
ENTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.25x
Industry
5.18x
ENTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.2M
Profit Margin
0%
ENTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ENTX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$11.6M
Liabilities
$1.5M
Debt to equity
0.15
ENTX's short-term assets ($11.37M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENTX's short-term assets ($11.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
-$11.0k
Financing
$0.0
ENTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ENTX vs Biotech Stocks
Entera Bio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.